

Early Clinical and Economic Outcomes of Patients Undergoing Living Donor Nephrectomy in the United States

Amy L. Friedman, MD; Kevin Cheung, BEng, MSc; Sanziana A. Roman, MD; Julie Ann Sosa, MD

Background: Efforts to maximize kidney transplantation are tempered by concern for the live donor's safety. Case series and center surveys exist, but national aggregate data are lacking. We sought to determine predictors of early clinical and economic outcomes following living donor nephrectomy.

Design: A retrospective cross-sectional analysis using 1999-2005 discharge data from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample was performed. Cases were identified by *International Classification of Diseases, Ninth Revision (ICD-9)*, codes. Clinical and economic outcomes were analyzed with regard to patient and provider characteristics using bivariate and multivariate regression analyses.

Setting: Healthcare Cost and Utilization Project Nationwide Inpatient Sample.

Patients: Patients undergoing living donor nephrectomy, identified by the *ICD-9* codes.

Interventions: Clinical and economic outcomes were analyzed with regard to patient and provider characteristics using bivariate and multivariate regression analyses.

Main Outcome Measures: In-hospital complications, mortality, mean length of stay (LOS), and mean total hospital costs.

Results: A total of 6320 cases were identified with 0% mortality and a complication rate of 18.4%. The mean (SD) LOS was 3.3 (0.3) days, and the mean inpatient cost was \$10 708 (\$505). Independent predictors of donor complications included older age (odds ratio [OR], 1.01), male sex (OR, 1.19), Charlson Comorbidity Index of at least 1 (OR, 1.49), obesity (OR, 1.76), medium-size hospitals (OR, 1.88), and low-volume hospitals (OR, 1.37). Predictors of longer LOS included older age, female sex, Charlson score of at least 1, lower household income, low-volume and urban hospitals, and low-volume surgeons.

Conclusions: Kidney donation is associated with a low mortality rate but an 18% complication rate. Donation by those with advanced age or obesity is associated with higher risks. Informed consent should include discussion of these risks.

Arch Surg. 2010;145(4):356-362

Author Affiliations: Department of Surgery, State University of New York Upstate Medical University, Syracuse (Dr Friedman); School of Medicine, Queen's University, Kingston, Ontario, Canada (Mr Cheung); and Department of Surgery, Yale University School of Medicine, New Haven, Connecticut (Mr Cheung and Drs Roman and Sosa).

KIDNEY TRANSPLANTATION prolongs survival and improves the quality of life for patients with end-stage renal disease, but it is limited by the severe shortage of organs. Kidneys may be procured and transplanted from either living or deceased donors; consistently superior early outcomes, including graft function, lower rates of rejection, and reduced costs, are obtained with kidneys from living donors. Recipients of live donor kidneys also experience better long-term rates of patient and graft survival.¹⁻⁴ There has been an overall increase in the number of live donor nephrectomies performed in the United States over the past decade.^{5,6} Intense pressure to meet the demand for kidneys also has led some transplant centers to per-

form elective nephrectomies in donors who are elderly, have hypertension or glucose intolerance, or are obese.⁷⁻¹⁰

See Invited Critique at end of article

Kidney donation is not without risks to the live donor. Data from single-center institutional reports and surveys suggest that operative mortality is rare, but complications range from urinary tract infections to bowel injury and renal failure.² Use of laparoscopy is associated with lower morbidity, decreased postoperative pain, and shorter hospital length of stay (LOS) compared with open techniques.⁶ These data may need to be interpreted with caution, however, because a recent study¹¹ of specific techniques of renal artery stump ligation raised concerns about

potential severe postoperative bleeding in these patients. Studies to date have been generally small and possibly underpowered, with the largest study encompassing 3074 kidney donors from 28 institutions.⁵

We report the first study, to our knowledge, to measure early clinical and economic outcomes of patients undergoing living donor nephrectomy on a population level, and the association with sociodemographic and clinical patient and provider (hospital and surgeon) characteristics.

METHODS

This study is a retrospective cross-sectional analysis of 1999-2005 hospital discharge information obtained from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) database, a stratified 20% sample of inpatient admissions to acute care hospitals. The HCUP-NIS is the largest all-payer inpatient database in the United States and is maintained by the Agency for Health Care Research and Quality (AHRQ). *International Classification of Diseases, Ninth Revision (ICD-9)* diagnostic and procedure codes were used to abstract the cases of patients undergoing living kidney donation from the database. Living kidney donor nephrectomies were identified as elective cases with both a primary diagnosis of kidney donor (ICD-9 code: V59.4) and primary procedure of nephroureterectomy (ICD-9 code: 55.51).

Independent demographic variables included patient age, sex, race (white, black, Hispanic, and other, which included but was not limited to Asians, Pacific Islanders, and Native Americans), patient location (large urban, small urban, suburban, and rural), payer type (private insurance, Medicare, self-pay, and other), and household income (<\$36 000, \$36 000-\$44 999, \$45 000-\$58 999, and \geq \$59 000). These variables were predefined in the HCUP-NIS. Patient comorbidity was assessed using the Charlson Comorbidity Index and individual ICD-9 codes for obesity (ICD-9 codes: 27.800, 27.801) and hypertension (ICD-9 code: 40.19). The Charlson Comorbidity Index is based on 17 defined comorbidities. It is a well-validated measure of illness complexity and has been used extensively with discharge and claims data to predict short-term outcomes such as in-hospital mortality, blood transfusion, hospitalization charges, and LOS. Patients were identified as either having comorbidities (Charlson score \geq 1) or no comorbidities (Charlson score = 0).^{12,13}

Independent hospital-provider characteristics included hospital size (small, medium, and large), location (urban vs rural), geographic region (North, East, Midwest, and South), and teaching status (teaching vs nonteaching). Hospital size classification varied based on geographic region, location, and teaching status. For example, large hospitals ranged in size from more than 45 beds in rural hospitals in the West to more than 450 beds in urban, teaching hospitals in the South. Hospital volume was based on the mean number of living donor nephrectomies performed per year. High-volume hospitals were defined as the top 50th percentile of hospitals (\geq 20 cases/y). Surgeons were identified as the admitting physicians for patients undergoing elective living donor nephrectomy as the principal procedure. They were grouped according to the total number of living donor nephrectomies they performed per year during our 7-year study period. High-volume surgeons were defined as those in the top 25th percentile of surgeons (\geq 5 cases/y).

OUTCOME VARIABLES

Primary outcome variables were¹ in-hospital patient complications,² mean hospital LOS,³ total inpatient hospital costs,

adjusted to 2005 dollars,⁴ and in-hospital mortality. In-hospital patient complications were identified from the ICD-9 diagnostic codes present on the discharge records of the selected cases. Complications were categorized into bleeding, infection, genitourinary (GU tract), gastrointestinal (GI tract), respiratory tract, and other. Complications were treated as a dichotomous variable (none vs \geq 1); information regarding severity was not available. Total inpatient costs were calculated using the HCUP-NIS-adjusted, hospital-specific, cost-to-charge ratios. Costs were adjusted for inflation, converting all costs to 2005 dollars using rates from the Bureau of Labor Statistics.¹⁴

STATISTICAL ANALYSIS

Bivariate analysis of independent variables by outcomes was performed by χ^2 analysis for categorical variables and analysis of variance for continuous variables. Multivariate linear regression models were used to adjust for significant independent variables for LOS and total inpatient costs. The LOS and total inpatient costs were log transformed to correct for data skew and kurtosis. Multivariate logistic regression models were used to adjust for independent variables for inpatient mortality and complications. Statistical analyses were performed using SPSS software (version 13.0; SPSS Inc, Chicago, Illinois). The HCUP-NIS is publicly available and contains no personal identifying information; consequently, this study was deemed to be exempt from institutional review board approval at our institutions.

RESULTS

DEMOGRAPHIC AND CLINICAL CHARACTERISTICS

There were 6331 patients whose discharge coding indicated that they underwent elective unilateral donor nephrectomy in the HCUP-NIS from 1999 to 2005. Eleven of these cases were excluded because of the uncertainty of living kidney donation based on patient age and/or secondary diagnoses on the discharge record. Of these 11, 7 procedures were not performed at a United Network for Organ Sharing (UNOS) transplant center and were deemed unlikely to involve live donors. Two cases included total hepatectomies, suggesting erroneous coding for live donor nephrectomy, in lieu of a deceased donor kidney recovery. One patient had a renal malignant neoplasm, and this was the case interpreted to have been miscoded for type of nephrectomy. One patient was undergoing hemodialysis with a preoperative comorbidity of chronic renal failure, but there was no coding for other complications expected to be associated with such a severe outcome from a live donor nephrectomy. The total coding error rate for the diagnosis of live donor nephrectomy was 11 of 6331, or 0.2%.

The mean donor age was 40 years; 59% of donors were female (**Table 1**). Most of the donors (68%) were white; blacks represented 12%; Hispanics, 11%; and other minorities, 6%. Most donors were from a large city (60%); 44% had private insurance. Donors with Medicare comprised 13% of the population, 13% were self-pay, and 26% had another form of coverage. There was an increased number of donors in the higher income quartiles: 29% earned at least \$59 000 compared with 21% who earned

UNADJUSTED PATIENT OUTCOMES

Table 1. Patient and Provider Characteristics for Living Donor Nephrectomy, 1999-2005

Characteristic	No. (%)
Patient Demographics (n=6320)	
Age, mean (SD), y	40.0 (11)
Female sex	3625 (59)
Race	
White	3044 (68)
Black	534 (12)
Hispanic	483 (11)
Other	268 (6)
Household income, \$	
<35 999	649 (21)
36 000-44 999	733 (23)
45 000-58 999	855 (27)
>59 000	899 (29)
Patient location	
Large urban	1911 (60)
Small urban	821 (26)
Suburban	307 (10)
Rural	159 (5)
Payer	
Private insurance	2759 (44)
Self-pay	848 (13)
Medicare	815 (13)
Medicaid	93 (2)
No charge	86 (1)
Other ^a	1609 (26)
Clinical characteristics	
Charlson index \geq 1	304 (5)
Obesity	127 (2)
Hypertension	121 (2)
Laparoscopic technique	1288 (20)
Provider (Hospital and Surgeon) Characteristics	
Size	
Large	5405 (86)
Medium	690 (11)
Small	225 (4)
Urban location	6287 (99.5)
Region	
South	1922 (30)
Midwest	1503 (24)
Northeast	1453 (23)
West	1442 (23)
Teaching hospital	6018 (95)
High volume	5152 (82)
High surgeon volume ^b	2462 (39)

^aIncluding Workman's Compensation, Civilian Health and Medical Program of the Uniformed Services, and Civilian Health and Medical Program of the Department of Veterans Affairs, Title V.

^bHigh-volume surgeons were defined as those in the top 25th percentile of surgeons (\geq 5 cases/y).

less than \$35 999. Overall, donors were healthy; just 5% had a Charlson score of a least 1. Obesity and hypertension were each identified in 2% of donors.

Provider characteristics demonstrated that most living donor nephrectomies were performed at large (86%) urban (99.5%) teaching (95%) hospitals. High-volume hospitals performed 82% of the procedures, and 39% of the procedures were performed by high-volume surgeons. Only 20% of cases were coded as laparoscopic, although the number of laparoscopic cases increased over time (4% in 1999, 29% in 2004).

No patient in-hospital deaths were identified. The mean (SD) LOS was 3.3 (0.3) days, and the mean inpatient cost was \$10 708 (\$505). Over time, the mean LOS revealed a significant and steady decline from 3.9 (0.3) days in 1999 to 2.7 (0.4) days in 2005 ($P < .001$). The mean inpatient cost significantly increased over time (from \$9290 [\$331] in 2001 to \$10 832 [\$644] in 2005; $P < .001$). The overall complication rate was 18.4%. Gastrointestinal tract complications occurred in 6.1% of cases, respiratory complications in 4.5%, bleeding in 4.3%, infection in 4.2%, and GU tract complications in 1.7%. Conversion from laparoscopic to open technique was reported in 0.8% of cases.

Significant differences in unadjusted clinical and economic outcomes were identified among living kidney donors (**Table 2**). Patients experiencing a complication were significantly older than patients not experiencing one (41.3 years vs 39.7 years; $P < .001$). The same trend was observed for patients with bleeding and GI tract complications. Older age also was associated with an increased mean LOS ($P = .002$).

Male donors had higher total complication rates (20.0%) than their female counterparts (17.8%; $P = .03$). Men had higher GU tract and respiratory tract complication rates: 2.5% vs 1.3% for women ($P < .001$) and 5.8% vs 3.7% for women ($P < .001$), respectively. Costs were higher for male donors (\$10 740 vs \$10 391 for women; $P < .05$). However, the mean LOS was shorter for men than for women (3.2 vs 3.4 days, respectively; $P < .001$).

Patient comorbidity was associated with worse clinical and economic outcomes. Compared with patients without comorbidity (Charlson score=0), donors with Charlson scores of at least 1 had higher GU tract (3.3% vs 1.7%; $P = .03$), respiratory tract (6.9% vs 4.4%; $P = .04$), infectious (6.6% vs 4.0%; $P = .03$), and total (26% vs 18%; $P < .001$) complication rates. A Charlson score of at least 1 was associated with longer LOS (3.6 days vs 3.3 days for Charlson score=0; $P < .001$). Donor obesity and hypertension were associated with higher complication rates: 28.3% of obese patients had complications compared with 18.2% of nonobese patients ($P = .004$). Bleeding complications were seen more frequently in obese patients (7.9% vs 4.2%; $P < .05$) and hypertensive patients (9.9% vs 4.2% for normotensive patients; $P = .002$). Hypertensive patients also had more GI tract (11.6% vs 6.0%; $P = .01$) and total (28.9% vs 18.2%; $P = .003$) complications. They had longer LOS (3.6 days vs 3.3 days; $P < .05$) and higher inpatient costs (\$11 927 vs \$10 683; $P < .05$).

High-volume hospitals were associated with significantly lower complication rates, shorter LOS, and lower costs. High-volume surgeons had patients with shorter LOS (3.0 days vs 3.5 days; $P < .001$) and lower costs (\$10 096 vs \$11 093; $P < .001$) than their low-volume counterparts. No significant difference in complication rates was observed between low- and high-volume surgeons ($P < .68$).

MULTIVARIATE ANALYSIS

Independent predictors of sustaining a postoperative complication were older age, male sex, Charlson score of at

least 1, obesity, hypertension, and surgery at medium-size and low-volume hospitals (**Table 3**). Medium-size hospitals, obesity, Charlson comorbidity, and low hospital volume were the strongest predictors of higher complication rates, with odds ratios of 1.88, 1.76, 1.49, and 1.37, respectively.

When examining bleeding complications specifically, older age, female sex, hypertension, and low hospital volume were independent predictors of increased risk with odds ratios of 1.02, 1.31, 1.88, and 1.55, respectively (**Figure 1**). Factors associated with increased risk of genitourinary complications were male sex and Charlson score of at least 1 with odds ratios of 2.05 and 2.12, respectively (**Figure 2**).

Independent predictors of longer LOS included older age, female sex, lower household income, Charlson score of at least 1, surgery at low-volume and urban hospitals, and surgery by low-volume surgeons. Predictors of higher costs were older age, male sex, nonwhite race, higher household income, urban center, and surgery at low-volume and nonteaching hospitals (**Table 4**).

COMMENT

This study of patients undergoing living donor nephrectomy from the HCUP-NIS, 1999-2005, represents 15% (as expected) of the 42 185 living kidney donations reported to UNOS during the same time frame.¹⁵ The HCUP-NIS represents an unbiased random sampling of hospitals in the United States. There was a 0% in-hospital mortality rate, which is consistent with findings from other groups. The survey by Matas et al² of US transplant centers based on self-report has been considered the most accurate estimate of donor mortality; it elucidated a rate of 0.02%. Recently, Patel et al³ reported a 0% mortality rate for donor nephrectomies performed at nonprofit academic centers.

Donor nephrectomy was associated with an overall in-hospital complication rate of 18.4%. Independent predictors of outcome included donor-level (older age, male sex, Charlson score ≥ 1 , and obesity) and provider characteristics (medium-size and low-volume hospitals). Previously reported complication rates vary significantly; a review of 44 studies reported complication rates of 3% to 38% for open living donor nephrectomies, and 5% to 26% for laparoscopic living donor nephrectomies.⁶

Increasing demand for organs has translated into less restrictive and controversial exclusion criteria for living kidney donors. Transplant teams are exploring kidney donation from individuals with advanced age, obesity, or medically controlled hypertension.¹⁶ The decision to proceed with a donor nephrectomy must incorporate both the short-term consequences of the surgical procedure and the long-term implications of reduced renal mass and function. There is no consensus with regard to what constitutes a high-risk donor. In a 1997 single-center, retrospective study of patients undergoing open living donor nephrectomy, male sex, pleural entry, and weight greater than 100 kg were associated with perioperative complications. Age, smoking, operative blood loss, operative duration, and body mass index (BMI), calcu-

Table 2. Unadjusted Clinical and Economic Outcomes Following Living Donor Nephrectomy, 1999-2005^a

Characteristic	Complication Rate, %	P Value	LOS, d	P Value	Cost (2005\$)	P Value
Patient Characteristics (n=6320)						
Age, y						
≤30	16.8	<.001	3.2	<.01	10 740	.36
31-40	16.3		3.3		10 466	
41-50	19.2		3.3		10 616	
>50	22.9		3.4		10 817	
Sex						
Male	20.0	<.05	3.2	<.001	10 740	<.05
Female	17.8		3.4		10 391	
Race						
White	19.3	<.05	3.3	<.001	10 332	<.001
Black	21.5		3.4		11 125	
Hispanic	17.8		3.2		12 794	
Other	13.4		3.0		10 905	
Charlson index						
Score=0	18.0	<.001	3.3	<.001	10 706	.93
Score ≥ 1	26.0		3.6		10 735	
Obesity						
Not obese	18.2	<.01	3.3	.11	10 689	.14
Obese	28.3		3.5		11 603	
Hypertension						
Normotensive	18.2	<.01	3.3	<.05	10 683	<.05
Hypertensive	28.9		3.6		11 927	
Provider (Hospital and Surgeon) Characteristics						
Hospital location						
Rural	21.2	.68	2.6	<.001	12 205	.22
Urban	18.4		3.3		10 697	
Teaching status						
Nonteaching	22.2	.08	3.5	.02	13 082	<.001
Teaching	18.2		3.3		10 626	
Hospital volume						
Low	22.9	<.001	3.7	<.001	11 299	<.001
High	17.4		3.2		10 602	
Surgeon volume						
Low	18.7	.45	3.5	<.001	11 093	<.001
High ^b	18.0		3.0		10 096	

Abbreviations: LOS, length of stay; NS, not significant.

^aIn order to calculate actual n values for each cell in Table 2, the data in Table 1 and Table 2 need to be combined. Complications are not mutually exclusive.

^bHigh-volume surgeons were defined as those in the top 25th percentile of surgeons (≥ 5 cases/y).

lated as weight in kilograms divided by height in meters squared, were not found to be risk factors.¹ The study by Patel et al³ of open and laparoscopic nephrectomies determined that smoking, obesity, age older than 50 years, and a center volume of less than 50 cases per year were associated with increased morbidity among 3074 living donors, with a complication rate of 10.6%. Another retrospective study of hand-assisted laparoscopic living kidney donors compared patients with a BMI of less than 25 with those with a BMI greater than 35. Obese patients had longer operative times and more complications, but similar rates of conversion to an open operation, reoperation, and LOS compared with nonobese patients.¹⁷ Our data corroborate the increased risks for obese and relatively old donors. One recent meta-analysis¹⁸ found no difference in perioperative outcomes between donors with and without isolated medical abnormalities, but it was limited by small sample size in the analyzed studies.

The current study demonstrates that relatively low hospital volume of living donor nephrectomy is associated with

Table 3. Adjusted Odds Ratios (ORs) for All Complications Following Living Donor Nephrectomy, 1999-2005

Variable	OR (95% CI)	P Value
Age	1.01 (1.01-1.02)	<.001
Sex		
Male	1 [Reference]	
Female	0.84 (0.74-0.96)	.01
Race		
White	1 [Reference]	
Black	1.27 (1.01-1.60)	.04
Hispanic	0.97 (0.75-1.25)	.80
Other	0.71 (0.49-1.03)	.07
Comorbidities		
No comorbidities	1 [Reference]	
Charlson index ≥ 1	1.49 (1.14-1.96)	.004
Obesity	1.76 (1.18-2.62)	.006
Hypertension	1.49 (0.99-2.24)	.06
Hospital bed size		
Small	1 [Reference]	
Medium	1.88 (1.23-2.87)	.004
Large	1.47 (0.99-2.18)	.006
Hospital volume		
Low	1 [Reference]	
High	0.73 (0.62-0.83)	<.001
Provider (hospital and surgeon) characteristics		
High-volume hospitals	-0.13	<.001
Teaching hospitals	-0.06	<.001
High-volume surgeons ^a	-0.04	<.05

Abbreviations: CI, confidence interval; NS, not significant.
^aHigh-volume surgeons were defined as those in the top 25th percentile of surgeons (≥ 5 cases/y).




Figure 1. Odds ratios (ORs) of bleeding complications in patients who underwent living donor nephrectomy, 1999-2005. Error bars represent 95% confidence intervals. * $P < .05$.

higher donor complication rates, longer LOS, and increased costs. Patel et al⁵ reported similar outcomes associated with low-volume hospitals. The concept that hospital volume has an effect on clinical and economic outcome is not unique to living donor nephrectomy. Pancreatectomy, coronary artery bypass grafting, percutaneous coronary intervention, abdominal aortic aneurysm repair, and esophagectomy have better outcomes and lower costs when performed at high-volume centers.^{19,20}

The potential importance of surgeons' technical expertise for the safety and economic outcomes of donor nephrectomies recently has been embraced by the UNOS. New regulations have been issued requiring minimal case volumes for certification of each donor surgeon participating in nephrectomies performed at living donor kidney transplant programs.²¹ Our data do not support surgeon volume as an independent predictor of clinical




Figure 2. Odds ratios (ORs) for genitourinary tract complications in patients who underwent living donor nephrectomy, 1999-2005. Error bars represent 95% confidence intervals. * $P < .05$.

Table 4. Factors Associated With Higher In-Hospital Costs in Patients Undergoing Living Donor Nephrectomy, 1999-2005

Variable	β	P Value
Age	0.04	.02
Female	-0.04	.02
Race		
White	1 [Reference]	
Black	0.05	.001
Hispanic	0.14	<.001
Other	0.04	.02
Household income, \$		
<35 999	1 [Reference]	
36 000-44 999	0.06	<.001
45 000-58 999	0.07	<.001
>59 000	0.10	<.001
Patient location		
Large urban	1 [Reference]	
Small urban	-0.07	<.001
Suburban	-0.08	<.001
Rural	-0.05	<.001
Payer		
Medicare	1 [Reference]	
Private	-0.04	.09
Self-pay	0.11	<.001
Other	-0.03	.13
Clinical characteristics		
No comorbidities	1 [Reference]	
Hypertension	0.03	.06
Laparoscopic technique	0.07	<.001
Provider (hospital and surgeon) characteristics		
High-volume hospitals	-0.13	<.001
Teaching hospitals	-0.06	<.001
High-volume surgeons ^a	-0.04	.01

Abbreviation: NS, not significant.
^aHigh-volume surgeons were defined as those in the top 25th percentile of surgeons (≥ 5 cases/y).

outcomes, although patients of low-volume surgeons had longer LOS. However, this analysis relied on admitting physician coding, whereas living donor kidney transplants are usually conducted under the auspices of a transplant team. There may be discrepancies between the admitting physician on record and the actual surgeon performing the donor nephrectomy.

Several studies have reported decreased operative time, complications, and LOS with increased experience of the surgeon for the initial learning curve of a new technique, such as laparoscopic or hand-assisted nephrectomy. A retrospective study²² of 500 laparoscopic donor

nephrectomies performed by 2 surgeons showed that operative time and complication rates decreased after a surgeon had performed more than 150 procedures and were not associated with patient age, sex, BMI, or side of kidney procurement. Another retrospective study²³ of 381 laparoscopic living donor nephrectomies reported fewer complications, graft loss, and vascular thrombosis with increasing surgeon experience. Surgeon volume has been shown to serve as a proxy for experience in thyroidectomy, coronary artery bypass grafting, aortic aneurysm repair, esophagectomy, and pancreatectomy.²⁴ There is a paucity of evidence documenting a surgeon-volume outcome association for donor nephrectomy outside of the learning curve observed among surgeons training to use the laparoscopic approach. It is reasonable that increased cumulative experience with open and/or laparoscopic nephrectomy would predict improved patient outcomes.

Low-volume donor nephrectomy centers are associated with poor short-term outcomes. Today, there is frequent collaboration of transplant surgeons and laparoscopists from the fields of general surgery or urology in the perioperative care of donor nephrectomy patients. This team approach may be beneficial for patients and hospitals. Larger centers may have more opportunities to foster such cross-specialty team efforts, which may account for some differences observed in this study between low- and high-volume centers.

Administrative databases have inherent limitations, such as errors in coding and sampling. The HCUP-NIS is a stratified 20% sample of US hospitals; however, it excludes Veteran Administration hospitals. This may account for the apparent undersampling of living kidney donors in our study. We excluded 0.17% of cases because they were consistent with coding errors. The procedure/diagnostic code error rate for the HCUP-NIS is 0.45% to 0.62%.²⁵ Laparoscopic technique was reported in 20.4% of cases. This is likely an underestimate of the true utilization of minimally invasive approaches, because even today there is no specific ICD-9 code for laparoscopic nephrectomy. The hand-assisted laparoscopic approach is thought to be safer and easier to master than exclusively laparoscopic techniques, and its use has increased.^{6,26} This technique could not be identified in the HCUP-NIS owing to the lack of specific codes. Readmissions are not captured; therefore, complication rates are likely underestimated. Identification of the true payer is complicated by assignment of donor costs to the recipient's insurance; this may be inaccurately coded at hospital discharge and, consequently, explain the large proportion of patients classified as "self-pay." Our demographic results, however, correlate with recent data from the Organ Procurement and Transplantation Network.²⁷ The diagnosis of obesity and hypertension among donors in the sample were based on comorbidity codes, not BMI or direct blood pressure measurements; therefore, their rates are likely underestimated.

Patients considering living kidney donation should be presented with an accurate assessment of their risks in order to obtain informed consent. Our data support the successful performance of living donor nephrectomies across numerous transplant centers in the United States,

with a reassuringly low mortality rate. Patients considering living donor nephrectomy should be advised that LOS, costs, and perioperative complication rates are generally lower at hospitals with the highest active volumes of living donor nephrectomies.

Living kidney donation is critical to expanding the donor pool given the increasing numbers of Americans with end-stage renal disease. These procedures would not be ethically justifiable if the donor's risk was known to be excessive.²⁸ The absence of mortality in this large donor population should be considered supportive evidence for continuation of this practice in low-risk donors. Kidney donations from individuals with increased risk of complications, such as older age, obesity, and hypertension, should be the subject of further study. Long-term outcomes, including renal function and quality of life, should be included in order to present patients with a balanced, informed medical opinion.

Accepted for Publication: April 27, 2009.

Correspondence: Amy L. Friedman, MD, Department of Surgery, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY 13210 (friedmaa@upstate.edu).

Author Contributions: *Study concept and design:* Friedman, Cheung, and Sosa. *Acquisition of data:* Cheung and Sosa. *Analysis and interpretation of data:* Friedman, Cheung, Roman, and Sosa. *Drafting of the manuscript:* Friedman, Cheung, Roman, and Sosa. *Critical revision of the manuscript for important intellectual content:* Friedman, Cheung, Roman, and Sosa. *Statistical analysis:* Cheung and Sosa. *Administrative, technical, and material support:* Friedman, Cheung, Roman, and Sosa. *Study supervision:* Friedman, Roman, and Sosa.

Financial Disclosure: None reported.

REFERENCES

1. Johnson EM, Remualdo MJ, Gillingham KJ, Dahms RA, Najarian JS, Matas AJ. Complications and risks of living donor nephrectomy. *Transplantation*. 1997; 64(8):1124-1128.
2. Matas AJ, Payne W, Sutherland D, et al. 2,500 living donor kidney transplants: a single-center experience. *Ann Surg*. 2001;234(2):149-164.
3. Ratner LE, Buell J, Kuo P. Laparoscopic donor nephrectomy: pro. *Transplantation*. 2000;70(10):1544-1546.
4. Terasaki PI, Cecka J, Gjertson D, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. *N Engl J Med*. 1995;333(6): 333-336.
5. Patel S, Cassuto J, Orloff M, et al. Minimizing morbidity of organ donation: analysis of factors for perioperative complications after living-donor nephrectomy in the United States. *Transplantation*. 2008;85(4):561-565.
6. Toohar RL, Rao M, Scott D, et al. A systematic review of laparoscopic live-donor nephrectomy. *Transplantation*. 2004;78(3):404-414.
7. Jacobs SC, Cho E, Dunkin BJ, et al. Laparoscopic nephrectomy in the markedly obese living renal donor. *Urology*. 2000;56(6):926-929.
8. Rea DJ, Heimbach JK, Grande JP, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. *Kidney Int*. 2006;70(9):1636-1641.
9. Textor SC, Taler S, Driscoll N, et al. Blood pressure and renal function after kidney donation from hypertensive living donors. *Transplantation*. 2004;78(2): 276-282.
10. Textor SC, Taler SJ, Larson TS, et al. Blood pressure evaluation among older living kidney donors. *J Am Soc Nephrol*. 2003;14(8):2159-2167.
11. Friedman AL, Peters TG, Jones KW, Boulware LE, Ratner LE. Fatal and nonfatal hemorrhagic complications of living kidney donation. *Ann Surg*. 2006;243 (1):126-130.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383.

13. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in *ICD-9-CM* and *ICD-10* administrative data. *Med Care*. 2005;43(11):1130-1139.
14. Overview of BLS statistics on inflation and consumer spending. Bureau of Labor Statistics Web site. www.bls.gov/bls/inflation.htm. Accessed November 27, 2007.
15. United Network for Organ Sharing national data, 2007. Organ Procurement and Transplantation Network Web site. <http://www.optn.org/latestData/step2.asp>. Accessed November 27, 2007.
16. Mandelbrot DA, Pavlakis M, Danovitch GM, et al. The medical evaluation of living kidney donors: a survey of US transplant centers. *Am J Transplant*. 2007;7(10):2333-2343.
17. Heimbach JK, Taler S, Prieto M, et al. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. *Am J Transplant*. 2005;5(5):1057-1064.
18. Young A, Storsley L, Garg A, et al. Health outcomes for living kidney donors with isolated medical abnormalities: a systematic review. *Am J Transplant*. 2008;8(9):1878-1890.
19. Birkmeyer JD, Finlayson EV, Birkmeyer CM. Volume standards for high-risk surgical procedures: potential benefits of the Leapfrog initiative. *Surgery*. 2001;130(3):415-422.
20. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. *N Engl J Med*. 2002;346(15):1128-1137.
21. Bylaws appendix B attachment I: designated transplant program criteria. United Network for Organ Sharing (UNOS) Web site. <http://unos.org/policiesandbylaws/bylaws.asp?resources=true>. Accessed November 15, 2007.
22. Chin EH, Hazzan D, Herron D, et al. Laparoscopic donor nephrectomy: intraoperative safety, immediate morbidity, and delayed complications with 500 cases. *Surg Endosc*. 2007;21(4):521-526.
23. Su LM, Ratner L, Montgomery R, et al. Laparoscopic live donor nephrectomy: trends in donor and recipient morbidity following 381 consecutive cases. *Ann Surg*. 2004;240(2):358-363.
24. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. *N Engl J Med*. 2003;349(22):2117-2127.
25. Healthcare Cost and Utilization Project (HCUP): HCUP Nationwide Inpatient Sample (NIS) Data Quality Reports: 1999-2005. Agency for Healthcare Research and Quality Web site. <http://www.hcup-us.ahrq.gov/db/nation/nis/nisrelatedreports.jsp>. Accessed July 23, 2007.
26. Davis CL, Delmonico FL. Living-donor kidney transplantation: a review of the current practices for the live donor. *J Am Soc Nephrol*. 2005;16(7):2098-2110.
27. Wainright J, Davis CL. Short-term complications in recent living kidney donors. *Am J Transplant*. 2008;8(S2):282.
28. Boulware LE, Ratner LE, Sosa J, Cooper LA, LaVeist TA, Powe NR. Determinants of willingness to donate living related and cadaveric organs: identifying opportunities for intervention. *Transplantation*. 2002;73(10):1683-1691.

INVITED CRITIQUE

Is It Safe to Donate a Kidney?

Approximately 6000 live donor nephrectomies are performed in the United States annually. Donor safety is of paramount importance. Therefore, there is a need to collect, analyze, and track donor morbidity and mortality to ensure patient safety. Reliable data confirming living kidney donor safety are important to be able to provide educational information for prospective donors and their families.

To my knowledge, Friedman et al are the first to report the use of a population-based approach to obtain this information by analyzing data derived from *International Classification of Diseases, Ninth Revision* codes in the HCUP-NIS. This is a laudable effort. Of 6320 living donations, there were no donor deaths, an 18.4% complication rate, and a mean (SD) duration of hospitalization of 3.3 (0.3) days. However, there are a number of important limitations to this approach. First, complications are not segregated by severity. Second, there is no consistency in how centers define their complications. Third, the data cannot be wholly verified for accuracy because they are derived from billing information and not confirmed by clinicians. As the name of the database implies, only in-patient data have been examined. The more difficult topic of the long-term consequences of living kidney donation is not addressed.

So, how do we reliably obtain this information regarding the overall safety of living kidney donation? Establishment of donor registries has been proposed.¹ Yet, significant problems exist associated with attempting to follow presumably healthy donors long term in large enough numbers to see statistically significant differences in outcomes.² Also, there is a lack of funding for such an enterprise. However, we can rest assured that Friedman et al have reconfirmed the appropriately extremely low mortality of living kidney donation despite a general trend to expand inclusion criteria and the dramatic changes in operative technique that have occurred during the study period.

Lloyd E. Ratner, MD

Author Affiliation: Department of Surgery, Columbia University, New York, New York.

Correspondence: Dr Ratner, Department of Surgery, Columbia University, 622 W 168th St, PH14-408, New York, NY 10032 (lr2182@columbia.edu).

Financial Disclosure: None reported.

1. Matas AJ, Bartlett ST, Leichtman AB, Delmonico FL. Morbidity and mortality after living kidney donation, 1999-2001: survey of United States transplant centers. *Am J Transplant*. 2003;3(7):830-834.
2. Ratner LE. Report card on living kidney donation. *Am J Transplant*. 2003;3(7):773-774.